Contracts › 75A50123C00056
75A50123C00056: Advance the Development of Potent, Cross-Reactive Multispecific Antibodies for the Prep Countermeasure of Covid-19 and Seasonal and Highly Pathogenic Avian Influenza.
Awarded to Modex Therapeutics, Inc by Office of Assistant Secretary for Preparedness and Response.
$103.5Mobligated
$198.5Mpotential value
29 February 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50123C00056 |
|---|---|
| Awardee | Modex Therapeutics, Inc |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN13 Health R&D Services; Health Care Services; Experimental Development |
| Place of performance | MA |
| Offers received | 1 |
| Period of performance | 27 September 2023 to 29 February 2028 |
| Potential end | 18 January 2030 |
| Estimated recompete solicitation | ~Q3 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record